Cancer is the leading disease with many victims worldwide, with around 40% of the population diagnosed with a type of cancer at some point in life. The main characteristic of the disease is its irregular and fast cell division that the body can not control, making tumor formations hard to control.
Depending on the localization of the cell division, cancer comes in different forms and attacks a variety of human organs. To curb that, scientists worldwide are trying to create a perfect formula to fight cancer by using new technology and equipment. One of which is C2i Genomics, a cancer intelligence company using AI technology that aims to monitor the disease with small amounts of blood.
After #tumor has been #removed, tiny traces of #cancer can still remain in the #bloodstream. A #bloodtest from #C2i Genomics prevent errors done by #oncologists by quantifying the minimal residual #disease left behind in cancer patients after #surgery . #openaccess #peerreview pic.twitter.com/Yb91Vqa8ZE
— Journal of Clinical Chem. and Laboratory Medicine (@JClinchem) April 19, 2022
AI technology and cancer monitoring
The team of researchers in C2i Genomics invented an AI monitoring system detecting minimal residual diseases (MRD). By only taking 2-3ml of blood, patients receive complete genomic analysis that detects potential cancer cell presence. Additionally, liquid biopsy can detect cancer in the early stage. As a result, this gives enough time to stop the disease from spreading to the whole organism.
With the new AI technology, cancer monitoring of persisting cancer cells during treatment is possible. The new ultra-sensitive methods can scan the whole genome and nucleotide base pairs. By scanning the whole genome, the sensitivity of C2i Genomics’ method is 100 times greater than other alternative methods used for cancer monitoring.
Cancer rates in India are at an epidemic level. There is no greater time to announce our partnership with @karkinoshealth. Together we're bringing AI-powered cancer detection & monitoring to India with C2inform, the first whole-genome sequencing MRD test. https://t.co/2ZTy1Js1yP
— C2i Genomics (@C2iGenomics) June 2, 2022
C2i Genomics has established partnerships with the leading cancer centers in the world that conduct active trials for determining cancer types. The following describes how C2i Genomics’ procedure works after a patient is diagnosed with cancer:
- After a biopsy is done, a personalized DNA signature is created for each patient using the whole genomic sequence.
- With the help of AI technology, they define the diagnosis with the blood samples taken from the patient. Blood from the patient should be collected before, during, and after the cancer treatment.
- The MRD is provided to the clinician who will inform whether the person needs additional treatment or surgery after the monitoring process.
Photo credits: The image is owned by C2i Genomics and has ben provided for press usage.
Source: WebWire
